Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders

•Meta-analysis shows that PGTs, compared to TAU, appears to be useful tools in setting more effective therapies for major depressive disorder.•No significant results emerged in the metanalysis regarding the comparison of PGT versus TAU in terms of efficacy in the treatment of bipolar disorder.•The r...

Full description

Saved in:

Bibliographic Details
Published in:	Psychiatry research Vol. 311; p. 114482
Main Authors:	Ielmini, Marta, Caselli, Ivano, Critelli, Flavio, Mattia, Michele, Bellini, Alessandro, Callegari, Camilla
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier B.V 01-05-2022
Subjects:	bipolar disorder Bipolar Disorder - drug therapy Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Humans Major depressive disorder Mood Disorders - drug therapy personalized medicine pharmacogenetic testing Pharmacogenomic Testing pharmacogenomics Quality of Life bipolar disorder pharmacogenomics Major depressive disorder pharmacogenetic testing personalized medicine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Meta-analysis shows that PGTs, compared to TAU, appears to be useful tools in setting more effective therapies for major depressive disorder.•No significant results emerged in the metanalysis regarding the comparison of PGT versus TAU in terms of efficacy in the treatment of bipolar disorder.•The review seems to give promising data dealing with the use of PGT to improve tolerability in the treatment of mood disorder. Bipolar Disorder (BD) and Major Depressive Disorder (MDD) have a huge impact on functioning and quality of life; moreover, they are linked to extensive direct and indirect costs. This systematic review with meta-analysis aims to evaluate the utility of pharmacogenetic tests (PGT) in terms of efficacy and tolerability into the routine clinical treatment of mood disorders. The first part of the review is a qualitative overview of the PGTs used in the included studies. The second part aims to compare, in terms of efficacy and tolerability, patients affected by BD and MDD treated as usual (TAU), according to the clinicians’ prescribing attitude, versus patients whose psychopharmacological treatments were set up following the PGT suggestions. 6 studies on MDD and 2 studies on BD were included. Regarding MDD, the meta-analysis shows a significantly higher number of patients achieving better outcome in terms of efficacy, through the evaluation of response rate and remission rate at the HDRS (Hamilton Depression Rating Scale) in the group of patients treated under the PGT suggestions; regarding BD the meta-analysis does not show any significant difference in terms of efficacy. In terms of adverse events, the available data suggest promising results about the utility of PGT to set more tolerated therapies. Although the limited number of studies, results confirm the importance of PGT in setting up psychopharmacological therapies as a support to clinicians’ choices.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-1 ObjectType-Article-3 ObjectType-Undefined-4
ISSN:	0165-1781 1872-7123
DOI:	10.1016/j.psychres.2022.114482